Innovative engineering of superoxide dismutase for enhanced cardioprotective biocatalysis in myocardial ischemia-reperfusion injury.

The present research compares the stability, catalytic activity, and cardioprotective benefits of the designed superoxide dismutase (SOD) variation SOD-M3 to those of the naturally occurring enzyme, along with additional alternatives. SOD-M3 exhibited a 51.5 % increase in expression yield, reaching 50 mg/L, compared to the wild-type's 33 mg/L. In structural biology, the average distance between atoms of stacked proteins or molecules is measured by RMSD. Testing the precision of protein-ligand docking models is a typical application. The projected structure closely resembles the reference or native structure when the RMSD is low. The enzyme's durability improved significantly, resulting in negligible aggregation in the Size Exclusion Chromatography (SEC) and root mean square deviation (RMSD) of 2.1 Å. SOD-M3 catalytically increased superoxide radical scavenging capability by 40 % and inhibited nitroblue tetrazolium (NBT) reduction by 90 % at 1 μg/mL concentration. The material exhibited increased stability, as seen by its decomposition temperature (Tm) of about 80 °C, as opposed to 65 °C in the wild-type strains. In cardiomyocyte protection experiments, SOD-M3 reduced lactate dehydrogenase (LDH) production by 55 % while decreasing reactive oxygen species (ROS) concentrations by 60 %. Since a 51.5 % increase in expression yield for SOD-M3 indicates improved production efficiency, which makes large-scale manufacturing more viable for clinical applications, it is therapeutically essential. Higher expression yields mean more cost-effective manufacture for enzyme-based therapy research and commercialization. In vivo, SOD-M3 decreased myocardial infarction diameter by 44 % while improving cardiac function, including increased ejection percentage and fractional contraction. The histopathological investigation revealed undamaged heart tissue and less necrotic areas. The results reported here demonstrate SOD-M3's superior activity of enzymes, cardioprotective perspective, and stability, making it a promising therapeutic alternative for illnesses related to cellular oxidation & ischemic cardiac diseases. An increase in enzyme concentrations can enhance the obtaining of reactive oxygen species (ROS), which build up during ischaemia episodes; therefore, this increase is essential. Improving the enzyme's solubility and stability by site-directed modifications makes SOD-M3 more stable and effective in physiological circumstances where its activity is crucial for therapeutic efficacy maximization. A further benefit of increased expression yield is that it can lower manufacturing costs, which will help get SOD-M3 into clinical settings. These modifications raise SOD-M3's cardioprotective potential, making it a strong contender for novel therapies against cardiac ischemia-reperfusion impacts.